Anti-Mycobacterium leprae activity of several quinolones studied in the mouse.
The anti-Mycobacterium leprae activity of several fluoroquinolones (A-56619, A-56620, ofloxacin, fleroxacin, lomefloxacin, temafloxacin, tosufloxacin, and PD-117596) was studied in the mouse. In a dosage of 150 mg/kg administered daily, A-56619 is active and A-56620 is inactive against M. leprae. Ofloxacin administered daily for 2 weeks at 300 mg/kg is bactericidal. The minimal effective dose of PD-117596, lomefloxacin and temafloxacin is less than 37.5 mg/kg. When administered at 300 mg/kg at monthly intervals temafloxacin, PD-117596, and ofloxacin are bacteriostatic; while fleroxacin and lomefloxacin are bactericidal. Tosufloxacin is less active than the other quinolones included in the present study.
Pattyn
S R
SR
Institute for Tropical Medicine, Antwerp, Belgium.
D000818:Animals; D000890:Anti-Infective Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002939:Ciprofloxacin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D016576:Fleroxacin / Q000494:pharmacology / Q000627:therapeutic use; D024841:Fluoroquinolones; D007918:Leprosy / Q000188:drug therapy*; D051379:Mice; D009166:Mycobacterium leprae / Q000187:drug effects*; D015363:Quinolones / Q000494:pharmacology / Q000627:therapeutic use
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; C054745:temafloxacin; D002939:Ciprofloxacin; C047225:difloxacin; C053091:lomefloxacin; D016576:Fleroxacin; C047224:sarafloxacin